Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 10/20 | 0.63 |
| ▸ | PTGER3 | P43115 | 7/20 | 0.63 |
| ▸ | PTGER2 | P43116 | 6/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2211312 | 0.90 | PTGER4 (0.62) | PTGER4PTGER3PTGER2 | |
| SCHEMBL4309176 | 0.86 | PTGER4 (0.53) | PTGER4PTGER3PTGER2 | |
| SCHEMBL5533104 | 0.85 | PTGER4 (0.54) | PTGER4PTGER3PTGER2 | |
| SCHEMBL3680191 | 0.85 | PTGER4 (0.69) | PTGER4PTGER3PTGER2 | |
| SCHEMBL12288890 | 0.81 | PTGER4 (0.63) | PTGER4PTGER3PTGER2 | |
| SCHEMBL5735404 | 0.77 | PTGER4 (1.00) | PTGER4PTGER3PTGER2 | |
| SCHEMBL5735415 | 0.77 | PTGER4 (1.00) | PTGER4PTGER3PTGER2 | |
| SCHEMBL2207666 | 0.77 | PTGER4 (0.47) | PTGER4PTGER3PTGER2 | |
| SCHEMBL2207663 | 0.77 | PTGER4 (0.47) | PTGER4PTGER3PTGER2 | |
| SCHEMBL5764418 | 0.76 | PTGER4 (0.53) | PTGER4PTGER3PTGER2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110237511-A1 | EP4 Receptor Agonist, Compositions and Methods Thereof | MERCK FROSST CANADA (CA) | 2011-09-29 | — | — | US | claimed |
| EP-1613621-B1 | PROSTAGLANDIN ANALOGS AS EP4 RECEPTOR AGONISTS | MERCK FROSST CANADA LTD (CA) | 2010-07-21 | — | — | EP | claimed |
| US-7238710-B2 | EP4 receptor agonist, compositions and methods thereof | MERCK FROSST CANADA, LTD. (CA) | 2007-07-03 | — | — | US | claimed |
| US-20050227969-A1 | EP4 receptor agonist, compositions and methods thereof | MERCK CANADA INC. (CA) | 2005-10-13 | — | — | US | claimed |
| WO-2004085431-A1 | PROSTAGLANDIN ANALOGS AS EP4 RECEPTOR ANTAGONISTS | MERCK FROSST CANADA LTD. (CA) | 2004-10-07 | — | — | WO | claimed |
| US-20040198701-A1 | EP4 receptor agonist, compositions and methods thereof | MERCK CANADA INC. (CA) | 2004-10-07 | — | — | US | claimed |
| US-20110237511-A1 | EP4 Receptor Agonist, Compositions and Methods Thereof | MERCK FROSST CANADA (CA) | 2011-09-29 | — | — | US | disclosed |
| US-RE42562-E1 | EP4 receptor agonist, compositions and methods thereof | MERCK FROSST CANADA (CA) | 2011-07-19 | — | — | US | disclosed |
| EP-1613621-B1 | PROSTAGLANDIN ANALOGS AS EP4 RECEPTOR AGONISTS | MERCK FROSST CANADA LTD (CA) | 2010-07-21 | — | — | EP | disclosed |
| US-7238710-B2 | EP4 receptor agonist, compositions and methods thereof | MERCK FROSST CANADA, LTD. (CA) | 2007-07-03 | — | — | US | disclosed |
| US-7053085-B2 | A piperidin-2-one, 1,3-oxazinan-2-one, or 1,3-thiazinan-2-one compound for treatment of glaucoma, mediating the bone modeling and remodeling processes of the osteoblasts and osteoclasts; 7-{(4S)-4-[(3R)-3-hydroxy-4-phenylbutyl]-2-oxo-1,3-oxazinan-3-yl}heptanoic acid; side effect reduction | MERCK & CO. INC. (US) | 2006-05-30 | — | — | US | disclosed |
| US-20050227969-A1 | EP4 receptor agonist, compositions and methods thereof | MERCK CANADA INC. (CA) | 2005-10-13 | — | — | US | disclosed |
| US-20040198701-A1 | EP4 receptor agonist, compositions and methods thereof | MERCK CANADA INC. (CA) | 2004-10-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040198701-A1 | EP4 receptor agonist, compositions and methods thereof | PTGER4, PTGER1, PTGER3 | PTGER4 1/4885PTGER3 3/4885PTGER2 4/4885 |
| US-20110237511-A1 | EP4 Receptor Agonist, Compositions and Methods Thereof | PTGER4, PTGER1, PTGER3 | PTGER4 1/4885PTGER3 3/4885PTGER2 4/4885 |
| US-20050227969-A1 | EP4 receptor agonist, compositions and methods thereof | PTGER4, PTGER1, PTGER3 | PTGER4 1/4885PTGER3 3/4885PTGER2 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.